BR0011503A - Induction of vascular endothelial growth factor (vdgf) by serine protein / threonine kinase akt - Google Patents

Induction of vascular endothelial growth factor (vdgf) by serine protein / threonine kinase akt

Info

Publication number
BR0011503A
BR0011503A BR0011503-7A BR0011503A BR0011503A BR 0011503 A BR0011503 A BR 0011503A BR 0011503 A BR0011503 A BR 0011503A BR 0011503 A BR0011503 A BR 0011503A
Authority
BR
Brazil
Prior art keywords
induction
growth factor
vdgf
vascular endothelial
endothelial growth
Prior art date
Application number
BR0011503-7A
Other languages
Portuguese (pt)
Inventor
Kun Guo
Yuri Ivashchenko
Kenneth Clark
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of BR0011503A publication Critical patent/BR0011503A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Patente de Invenção: "INDUçãO DO FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR (VDGF) PELA PROTEìNA DE SERINA/TREONINA CINASE AKT". A presente invenção diz respeito a métodos e composições para a angiogênese terapêutica. Mais especialmente, esta invenção é dirigida à indução da expressão do fator de crescimento endotelial vascular (VEGF) pela proteína cinase AKT de serina/treonina. Preferivelmente, as composições e métodos de acordo com a invenção compreendem um ácido nucléico codificando AKT, e a sua administração.Patent of Invention: "INDUCTION OF VASCULAR ENDTHELIAL GROWTH FACTOR (VDGF) BY SERINE / TREONINE KINASE AKT PROTEIN". The present invention relates to methods and compositions for therapeutic angiogenesis. More particularly, this invention is directed to the induction of vascular endothelial growth factor (VEGF) expression by the serine / threonine protein kinase AKT. Preferably, the compositions and methods according to the invention comprise an AKT-encoding nucleic acid, and their administration.

BR0011503-7A 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vdgf) by serine protein / threonine kinase akt BR0011503A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13872499P 1999-06-11 1999-06-11
GB9926058 1999-11-03
PCT/US2000/015098 WO2000077190A2 (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Publications (1)

Publication Number Publication Date
BR0011503A true BR0011503A (en) 2002-03-05

Family

ID=26316052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011503-7A BR0011503A (en) 1999-06-11 2000-06-01 Induction of vascular endothelial growth factor (vdgf) by serine protein / threonine kinase akt

Country Status (17)

Country Link
EP (1) EP1187911A2 (en)
JP (1) JP2003530818A (en)
KR (1) KR20020012270A (en)
CN (1) CN1360629A (en)
AU (1) AU773450B2 (en)
BR (1) BR0011503A (en)
CA (1) CA2376630A1 (en)
CZ (1) CZ20014444A3 (en)
HK (1) HK1041500A1 (en)
HU (1) HUP0201663A3 (en)
IL (1) IL146730A0 (en)
MX (1) MXPA01012748A (en)
NO (1) NO20016025L (en)
NZ (1) NZ516054A (en)
PL (1) PL352859A1 (en)
SI (1) SI20978A (en)
WO (1) WO2000077190A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1144600T1 (en) * 1999-03-19 2008-12-31 Aventis Pharma Inc Akt-3 nucleic acids, polypeptides, and uses thereof
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
HUP0200799A3 (en) * 1999-04-16 2004-11-29 Univ Yale New Haven Enos mutations useful for gene therapy and therapeutic screening
US6187586B1 (en) * 1999-12-29 2001-02-13 Isis Pharmaceuticals, Inc. Antisense modulation of AKT-3 expression
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
WO2001064235A1 (en) * 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1144600T1 (en) * 1999-03-19 2008-12-31 Aventis Pharma Inc Akt-3 nucleic acids, polypeptides, and uses thereof

Also Published As

Publication number Publication date
KR20020012270A (en) 2002-02-15
PL352859A1 (en) 2003-09-08
MXPA01012748A (en) 2002-07-02
CN1360629A (en) 2002-07-24
CZ20014444A3 (en) 2002-05-15
JP2003530818A (en) 2003-10-21
AU773450B2 (en) 2004-05-27
EP1187911A2 (en) 2002-03-20
IL146730A0 (en) 2002-07-25
CA2376630A1 (en) 2000-12-21
HUP0201663A3 (en) 2005-01-28
AU5175800A (en) 2001-01-02
WO2000077190A2 (en) 2000-12-21
HUP0201663A2 (en) 2002-08-28
HK1041500A1 (en) 2002-07-12
NO20016025D0 (en) 2001-12-10
WO2000077190A3 (en) 2001-04-12
NO20016025L (en) 2002-02-08
NZ516054A (en) 2004-04-30
SI20978A (en) 2003-02-28

Similar Documents

Publication Publication Date Title
ATE309194T1 (en) NOVEL DICARBONIC ACID DERIVATIVES WITH PHARMACEUTICAL PROPERTIES
BR0011448A (en) Amide Substituted Imidazoquinolines
BR0214750A (en) Substituted thioether imidazoquinolines
BR0313176A (en) Pyrazole compositions useful as gsk-3 inhibitors
BR0208489A (en) N- (Arylsulfonyl) beta-amino acid derivatives having a substituted aminoethyl group, their preparation process and the pharmaceutical compositions containing them
BR0206955A (en) Cannabinoid Receptor Binders
BR0116047A (en) Heterocyclic Ether Substituted Imidazoquinolines
SI1532974T1 (en) Composition comprising 6-?á3-(1-adamantyl)-4-methoxyphenyl?å-2-naphthoic acid for the treatment of dermatological disorders
SI1536827T1 (en) Use of protein kinase n beta
EA200100524A1 (en) AMIDES OF ANTRANILIC ACID AND THEIR APPLICATION AS MEDICINES
BRPI0407999A (en) fused heteroaromatic compounds as inhibitors of growth transforming factor (tgf)
MXPA03009439A (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity.
BR0203172A (en) Therapeutic Agents for Achondroplasia
BR0012450A (en) Substituted benzimidazoles
WO2003020217A3 (en) Novel pyrazole analogs acting on cannabinoid receptors
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
BR9917038A (en) Compound, pharmaceutical composition, method of modulating chemokine receptor activity, method of treatment or prevention of inflammatory diseases, method of treatment or prevention of asthma and method of treatment or prevention of inflammatory disorders
WO2003035005A3 (en) Heteroindanes: a new class of potent cannabimimetic ligands
NO20042298L (en) Pharmaceutical preparations and their uses
SE9903544D0 (en) Novel compounds
NO20040511L (en) Aminoisoxazole derivatives as kinase inhibitors
BR9914360A (en) N-aralkylaminotetralins as ligands for neuropeptide receptor yy5
BR0211502A (en) Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Preparation Method
BR0210028A (en) Antibacterial agents
ATE301654T1 (en) NAPHTHYRIDINE DERIVATIVES

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.